NCT05366439

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge Model

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model

Detailed description

A Phase 1, double-blind, randomized, placebo-controlled study to assess the antiviral activity and safety of AT-752 in a Dengue Human Challenge Model

Conditions

• Dengue

Interventions

Type	Name	Description
DRUG	AT-752	Parallel Assignment
DRUG	Placebo Comparator	Parallel Assignment

Timeline

• Start date: 2022-04-22
• Primary completion: 2023-03-16
• Completion: 2023-03-16
• First posted: 2022-05-09
• Last updated: 2023-04-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study